Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases

Table 1

Characteristics of patients with prostate cancer without metastases (PC cM0) or with metastases (PC cM1).

	PC cM0	PC cM1
	43	47
Age (median; range)	69 (48–85)	74 (52–84)
PSA, ng/ml (median; range)	6.96 (0.31–44)	80.4 (0.52–674)
Gleason Score, (%)		—
≤6	7 (16.3)	—
7	31 (72.1)	1 (2.1)
≥8	5 (11.6)	4 (8.5)
T stage, (%)		—
pT2a	6 (14.0)	—
pT2b	1 (2.3)	—
pT2c	24 (55.8)	—
pT3a	9 (20.9)	—
pT3b	3 (7.0)	—
N stage, (%)
N0	41 (95.3)	20 (42.5)
N+	2 (4.7)	25 (53.2)
Nx	—	2 (4.3)
M stage, (%)
cM1b	—	47 (100)
cM1c	—	8 (17.0)
Castrate level, (%)
CSPC	—	11 (23.4)
CRPC	—	34 (72.3)
n.a.		2 (4.3)

T stage = primary tumor; N stage = lymph nodes; M stage = distant metastases; N0 = no regional lymph node metastasis; N1 = metastasis in regional lymph node(s); Nx = regional lymph nodes were not assessed; cM1b = bone metastases; cM1c = other metastases; CSPC = castration-sensitive prostate cancer; CRPC = castration-resistant prostate cancer; n.a. = not applicable.